The first innovative drug to be developed in Israel and to receive FDA approval, Copaxone® is a unique multiple sclerosis immunomodulator: the first and only non-interferon agent for the treatment of relapsing-remitting multiple sclerosis.  Copaxone® is licensed to Teva Pharmaceuticals Ltd.

• Indicated for Multiple Sclerosis COPAXONE represents a new class of drugs for the treatment of the disease.
• Copaxone is a synthetic copolymer acting as an immunomodulator.
• 1971: First Patent filed by Yeda.
• 1987: Licensed to Teva Pharmaceuticals Ltd.

Inventors of Copaxone are Prof. Ruth Arnon, Prof. Michael Sela and Dr. Dvora Teitelbaum

An antibody based therapy presenting synergism with conventional chemotherapy. The synergistic effect was invented at the Weizmann Institute. Erbitux was developed by ImClone Systems and approved by the FDA in 2001.

Erbitux is an antibody based therapy presenting synergism with conventional chemotherapy. 

• The synergistic effect was invented by Prof. Sela’s group at WIS between 1987-88.
• Erbitux was developed by ImClone Systems & approved by the FDA in 2001.
• Ongoing phase III studies in several new indications (e.g. CRC, SCCHN, NSCLC)